Fishman Jay A Ltd. MI Decreases Stock Position in Danaher Co. (NYSE:DHR)

Fishman Jay A Ltd. MI cut its stake in shares of Danaher Co. (NYSE:DHR) by 3.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,181 shares of the conglomerate’s stock after selling 475 shares during the quarter. Fishman Jay A Ltd. MI’s holdings in Danaher were worth $3,255,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of DHR. Fort Pitt Capital Group LLC increased its stake in shares of Danaher by 3.2% in the third quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock worth $66,194,000 after buying an additional 7,421 shares during the period. Good Life Advisors LLC bought a new stake in Danaher in the 3rd quarter worth $217,000. ORG Partners LLC grew its holdings in Danaher by 1,212.8% in the 4th quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock worth $636,000 after acquiring an additional 2,559 shares during the last quarter. Harvest Portfolios Group Inc. increased its position in shares of Danaher by 1.2% in the third quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock valued at $56,233,000 after acquiring an additional 2,465 shares during the period. Finally, Stifel Financial Corp raised its stake in shares of Danaher by 1.3% during the third quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock valued at $235,583,000 after acquiring an additional 11,216 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

Shares of Danaher stock opened at $201.15 on Wednesday. Danaher Co. has a 1 year low of $199.75 and a 1 year high of $281.70. The firm’s 50-day moving average is $231.96 and its 200 day moving average is $251.14. The stock has a market cap of $145.29 billion, a price-to-earnings ratio of 38.10, a PEG ratio of 2.68 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05.

Danaher (NYSE:DHR) last issued its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the prior year, the firm earned $2.09 EPS. Sell-side analysts anticipate that Danaher Co. will post 7.67 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Friday, December 27th were paid a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.54%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s dividend payout ratio is currently 20.45%.

Insider Activity

In other news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

DHR has been the subject of a number of recent analyst reports. Citigroup lowered their price target on Danaher from $285.00 to $265.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target for the company in a research note on Friday, December 13th. Stephens reissued an “overweight” rating and set a $315.00 price objective on shares of Danaher in a research report on Wednesday, October 23rd. Guggenheim initiated coverage on shares of Danaher in a report on Thursday, December 19th. They issued a “buy” rating and a $275.00 price objective for the company. Finally, Robert W. Baird reduced their price target on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Seven analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $278.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.